Cargando…

Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial

BACKGROUND AND RATIONALE: Idiopathic pulmonary fibrosis is a critical disease with a poor prognosis. Although different studies have been conducted for the treatment of idiopathic pulmonary fibrosis, limited treatments are available. Jin-shui Huan-xian granule (JHG), which is a Chinese medicine herb...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shu-guang, Yu, Xue-qing, Li, Jian-sheng, Xie, Yang, Zhang, Wei, Ban, Chengjun, Feng, Jihong, Wu, Lei, Lu, Xuechao, Zhao, Limin, Meng, Yong, Zhou, Miao, He, Yong, Luo, Weixian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438282/
https://www.ncbi.nlm.nih.gov/pubmed/36056382
http://dx.doi.org/10.1186/s13063-022-06684-0
_version_ 1784781794117156864
author Yang, Shu-guang
Yu, Xue-qing
Li, Jian-sheng
Xie, Yang
Zhang, Wei
Ban, Chengjun
Feng, Jihong
Wu, Lei
Lu, Xuechao
Zhao, Limin
Meng, Yong
Zhou, Miao
He, Yong
Luo, Weixian
author_facet Yang, Shu-guang
Yu, Xue-qing
Li, Jian-sheng
Xie, Yang
Zhang, Wei
Ban, Chengjun
Feng, Jihong
Wu, Lei
Lu, Xuechao
Zhao, Limin
Meng, Yong
Zhou, Miao
He, Yong
Luo, Weixian
author_sort Yang, Shu-guang
collection PubMed
description BACKGROUND AND RATIONALE: Idiopathic pulmonary fibrosis is a critical disease with a poor prognosis. Although different studies have been conducted for the treatment of idiopathic pulmonary fibrosis, limited treatments are available. Jin-shui Huan-xian granule (JHG), which is a Chinese medicine herbal compound, has shown promising efficacy in reducing frequencies of acute exacerbations, improving exercise capacity the quality of life of patients with idiopathic pulmonary fibrosis. This study is to evaluate the efficacy and safety of JHG for IPF. SUBJECTS AND METHODS: This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. A total of 312 idiopathic pulmonary fibrosis patients will be enrolled and randomly allocated to one of the two groups with 1:1. After a 2-week washout period, 52-week treatment will also be performed for all the patients. Patients in the experimental group and the control group will be given JHG and JHG placebo, respectively. Outcome measures including acute exacerbations, pulmonary function, dyspnea, exercise capacity, and quality of life will be evaluated in this study. DISCUSSION: Based on our previous study, it is hypothesized that JHG will reduce acute exacerbations; improve exercise capacity, pulmonary function, and quality of life; and delay the disease progression-free. High-level evidence-based support for TCM in IPF will also be obtained in this study. TRIAL REGISTRATION: ClinicalTrials.gov NCT04187690. Register on December 11, 2019
format Online
Article
Text
id pubmed-9438282
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94382822022-09-03 Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial Yang, Shu-guang Yu, Xue-qing Li, Jian-sheng Xie, Yang Zhang, Wei Ban, Chengjun Feng, Jihong Wu, Lei Lu, Xuechao Zhao, Limin Meng, Yong Zhou, Miao He, Yong Luo, Weixian Trials Study Protocol BACKGROUND AND RATIONALE: Idiopathic pulmonary fibrosis is a critical disease with a poor prognosis. Although different studies have been conducted for the treatment of idiopathic pulmonary fibrosis, limited treatments are available. Jin-shui Huan-xian granule (JHG), which is a Chinese medicine herbal compound, has shown promising efficacy in reducing frequencies of acute exacerbations, improving exercise capacity the quality of life of patients with idiopathic pulmonary fibrosis. This study is to evaluate the efficacy and safety of JHG for IPF. SUBJECTS AND METHODS: This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. A total of 312 idiopathic pulmonary fibrosis patients will be enrolled and randomly allocated to one of the two groups with 1:1. After a 2-week washout period, 52-week treatment will also be performed for all the patients. Patients in the experimental group and the control group will be given JHG and JHG placebo, respectively. Outcome measures including acute exacerbations, pulmonary function, dyspnea, exercise capacity, and quality of life will be evaluated in this study. DISCUSSION: Based on our previous study, it is hypothesized that JHG will reduce acute exacerbations; improve exercise capacity, pulmonary function, and quality of life; and delay the disease progression-free. High-level evidence-based support for TCM in IPF will also be obtained in this study. TRIAL REGISTRATION: ClinicalTrials.gov NCT04187690. Register on December 11, 2019 BioMed Central 2022-09-02 /pmc/articles/PMC9438282/ /pubmed/36056382 http://dx.doi.org/10.1186/s13063-022-06684-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Yang, Shu-guang
Yu, Xue-qing
Li, Jian-sheng
Xie, Yang
Zhang, Wei
Ban, Chengjun
Feng, Jihong
Wu, Lei
Lu, Xuechao
Zhao, Limin
Meng, Yong
Zhou, Miao
He, Yong
Luo, Weixian
Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
title Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
title_full Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
title_fullStr Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
title_full_unstemmed Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
title_short Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
title_sort efficacy and safety of jin-shui huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438282/
https://www.ncbi.nlm.nih.gov/pubmed/36056382
http://dx.doi.org/10.1186/s13063-022-06684-0
work_keys_str_mv AT yangshuguang efficacyandsafetyofjinshuihuanxiangranuleforidiopathicpulmonaryfibrosisstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT yuxueqing efficacyandsafetyofjinshuihuanxiangranuleforidiopathicpulmonaryfibrosisstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT lijiansheng efficacyandsafetyofjinshuihuanxiangranuleforidiopathicpulmonaryfibrosisstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT xieyang efficacyandsafetyofjinshuihuanxiangranuleforidiopathicpulmonaryfibrosisstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT zhangwei efficacyandsafetyofjinshuihuanxiangranuleforidiopathicpulmonaryfibrosisstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT banchengjun efficacyandsafetyofjinshuihuanxiangranuleforidiopathicpulmonaryfibrosisstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT fengjihong efficacyandsafetyofjinshuihuanxiangranuleforidiopathicpulmonaryfibrosisstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT wulei efficacyandsafetyofjinshuihuanxiangranuleforidiopathicpulmonaryfibrosisstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT luxuechao efficacyandsafetyofjinshuihuanxiangranuleforidiopathicpulmonaryfibrosisstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT zhaolimin efficacyandsafetyofjinshuihuanxiangranuleforidiopathicpulmonaryfibrosisstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT mengyong efficacyandsafetyofjinshuihuanxiangranuleforidiopathicpulmonaryfibrosisstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT zhoumiao efficacyandsafetyofjinshuihuanxiangranuleforidiopathicpulmonaryfibrosisstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT heyong efficacyandsafetyofjinshuihuanxiangranuleforidiopathicpulmonaryfibrosisstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT luoweixian efficacyandsafetyofjinshuihuanxiangranuleforidiopathicpulmonaryfibrosisstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial